Free Trial
NASDAQ:BLFS

BioLife Solutions (BLFS) Stock Price, News & Analysis

$23.79
-0.94 (-3.80%)
(As of 09/6/2024 ET)
Today's Range
$23.12
$24.80
50-Day Range
$19.19
$26.52
52-Week Range
$8.92
$26.73
Volume
362,177 shs
Average Volume
386,486 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.20

BioLife Solutions MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.1% Upside
$26.20 Price Target
Short Interest
Bearish
8.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.33mentions of BioLife Solutions in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$264,890 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.37) to ($0.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

745th out of 910 stocks

Electromedical Equipment Industry

16th out of 22 stocks

BLFS stock logo

About BioLife Solutions Stock (NASDAQ:BLFS)

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Stock Price History

BLFS Stock News Headlines

Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
BioLife Solutions Inc (BJX1.DU)
BioLife Is Cleaning Ship
Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2024
Today
9/07/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:BLFS
Employees
440
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.20
High Stock Price Target
$30.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+10.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-66,430,000.00
Pretax Margin
-51.03%

Debt

Sales & Book Value

Annual Sales
$139.96 million
Book Value
$6.97 per share

Miscellaneous

Free Float
45,055,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
1.85
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

BLFS Stock Analysis - Frequently Asked Questions

How have BLFS shares performed this year?

BioLife Solutions' stock was trading at $16.25 at the beginning of the year. Since then, BLFS shares have increased by 46.4% and is now trading at $23.79.
View the best growth stocks for 2024 here
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. The medical equipment provider had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative trailing twelve-month return on equity of 10.75%.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Who are BioLife Solutions' major shareholders?

BioLife Solutions' top institutional shareholders include Fred Alger Management LLC (3.43%), William Blair Investment Management LLC (3.41%), Millennium Management LLC (2.19%) and Dimensional Fund Advisors LP (1.73%). Insiders that own company stock include Casdin Partners Master Fund, L, Greef Roderick De, Michael Rice, Aby J Mathew, Karen A Foster, Troy Wichterman, Todd Berard, Geraint Phillips, Sarah Aebersold, Marcus Schulz, Amy Duross and Joseph C Schick.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE) and Rigel Pharmaceuticals (RIGL).

This page (NASDAQ:BLFS) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners